By David Cassak
As officials at Guidant Corp. have found themselves slipping behind rivals Johnson & Johnson and Boston Scientific Corp....
Guidant: The New Rules of the Device Game
As it seeks to capitalize on new opportunities in both its CRM and interventional businesses, Guidant also confronts a device industry whose rules are changing. The second of a two-part series.
More from Leadership
More from In Vivo
• By
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
• By
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
• By
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.